US FDA to discuss changes to cardiac devices needing 30-day notice, annual report
This article was originally published in Clinica
Executive Summary
The appropriate reporting mechanism that cardiovascular device sponsors should use to inform the US Food and Drug Administration of manufacturing changes they make to approved products are to be discussed at an FDA workshop on 28 August.